CDC22: A Protein Involved in T-cell Signaling and Cancer Progression

Target Name: CCDC22

NCBI ID: G28952

CCDC22

CDC22: A Protein Involved in T-cell Signaling and Cancer Progression

CCDC22 is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the superfamily of compact ribosome subfamily (SMTAF), which includes proteins that are involved in various cellular processes, including cell signaling, DNA replication, and protein translation.

One of the unique features of CCDC22 is its ability to interact with the protein p21, which is a negative regulator of the T-cell receptor signaling pathway. This interaction between CCDC22 and p21 suggests that CCDC22 may be involved in regulating the activity of T- cells, which are a critical immune cell that play a key role in defending against infection and disease.

Another potential role for CCDC22 is as a drug target. The ability of CCDC22 to interact with p21 suggests that targeting this protein may be a way to inhibit the activity of p21 and potentially lead to the activation of T-cells that are involved in disease. This suggests that CCDC22 may be a promising target for the development of new treatments for a variety of diseases.

In addition to its potential as a drug target, CCDC22 is also a potential biomarker. The expression of CCDC22 in various tissues suggests that this protein may be involved in the development and progression of a variety of diseases. For example, CCDC22 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that CCDC22 may be a useful biomarker for the diagnosis and treatment of these diseases.

Another potential application of CCDC22 is its use as a diagnostic tool. The expression of CCDC22 in various tissues makes it a potential target for diagnostic tests that are designed to detect the presence of this protein in these tissues. This suggests that CCDC22 may be a useful diagnostic tool for the diagnosis of various diseases, including cancer.

In conclusion, CCDC22 is a protein that is expressed in various tissues throughout the body and is involved in a variety of cellular processes. Its interaction with the protein p21 suggests that CCDC22 may be involved in the regulation of T-cell activity and could be a promising target for the development of new treatments for a variety of diseases. Its expression in various tissues also suggests that CCDC22 may be a useful biomarker for the diagnosis and treatment of various diseases. Further research is needed to fully understand the role of CCDC22 in these processes and to determine its potential as a drug or biomarker.

Protein Name: Coiled-coil Domain Containing 22

Functions: Involved in regulation of NF-kappa-B signaling. Promotes ubiquitination of I-kappa-B-kinase subunit IKBKB and its subsequent proteasomal degradation leading to NF-kappa-B activation; the function may involve association with COMMD8 and a CUL1-dependent E3 ubiquitin ligase complex. May down-regulate NF-kappa-B activity via association with COMMD1 and involving a CUL2-dependent E3 ubiquitin ligase complex. Regulates the cellular localization of COMM domain-containing proteins, such as COMMD1 and COMMD10 (PubMed:23563313). Component of the CCC complex, which is involved in the regulation of endosomal recycling of surface proteins, including integrins, signaling receptor and channels. The CCC complex associates with SNX17, retriever and WASH complexes to prevent lysosomal degradation and promote cell surface recycling of numerous cargos such as integrins ITGA5:ITGB1 (PubMed:28892079, PubMed:25355947). Plays a role in copper ion homeostasis. Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association within the CCC complex and cooperation with the WASH complex on early endosomes (PubMed:25355947)

The "CCDC22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets